ISSN 0303-5212
 

Original Research 
RMJ. 2023; 48(4): 805-808


Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy

Komal Mumtaz Malik, Kulsoom Farhat, Muhammad Asghar Khan, Bilal Ahmad, Shabana Ali, Mudassar Noor.

Abstract
Objective: To compare the glycemic control of a newer insulin co-formulation, insulin degludec aspart with the conventional premixed insulin therapy, in type 2 diabetes mellitus.
Methodology: We included 120 participants with documented type 2 diabetes, taking premixed insulin therapy. They were divided into two groups; Group B participants were switched to once-daily insulin degludec aspart whereas those in group A continued receiving biphasic insulin aspart. Glycemic control was assessed with Hemoglobin A1c levels, fasting, and post-prandial plasma glucose concentrations of the participants during a 12-week study period.
Results: HbA1c, Fasting and 2-hour post prandial plasma glucose concentrations were significantly reduced in participants taking insulin degludec aspart (p<0.05).
Conclusion: Use of degludec aspart has simplified dosage method, increased treatment compliance, and produced better clinical outcomes in Pakistani population.

Key words: Biphasic insulin aspart, glycemic control, insulin degludec aspart, type 2 diabetes mellitus.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Komal Mumtaz Malik
Articles by Kulsoom Farhat
Articles by Muhammad Asghar Khan
Articles by Bilal Ahmad
Articles by Shabana Ali
Articles by Mudassar Noor
on Google
on Google Scholar

How to Cite this Article
Pubmed Style

Malik KM, Farhat K, Khan MA, Ahmad B, Ali S, Noor M. Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy. RMJ. 2023; 48(4): 805-808.


Web Style

Malik KM, Farhat K, Khan MA, Ahmad B, Ali S, Noor M. Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy. https://www.rmj.org.pk/?mno=133351 [Access: December 15, 2023].


AMA (American Medical Association) Style

Malik KM, Farhat K, Khan MA, Ahmad B, Ali S, Noor M. Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy. RMJ. 2023; 48(4): 805-808.



Vancouver/ICMJE Style

Malik KM, Farhat K, Khan MA, Ahmad B, Ali S, Noor M. Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy. RMJ. (2023), [cited December 15, 2023]; 48(4): 805-808.



Harvard Style

Malik, K. M., Farhat, . K., Khan, . M. A., Ahmad, . B., Ali, . S. & Noor, . M. (2023) Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy. RMJ, 48 (4), 805-808.



Turabian Style

Malik, Komal Mumtaz, Kulsoom Farhat, Muhammad Asghar Khan, Bilal Ahmad, Shabana Ali, and Mudassar Noor. 2023. Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy. Rawal Medical Journal, 48 (4), 805-808.



Chicago Style

Malik, Komal Mumtaz, Kulsoom Farhat, Muhammad Asghar Khan, Bilal Ahmad, Shabana Ali, and Mudassar Noor. "Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy." Rawal Medical Journal 48 (2023), 805-808.



MLA (The Modern Language Association) Style

Malik, Komal Mumtaz, Kulsoom Farhat, Muhammad Asghar Khan, Bilal Ahmad, Shabana Ali, and Mudassar Noor. "Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy." Rawal Medical Journal 48.4 (2023), 805-808. Print.



APA (American Psychological Association) Style

Malik, K. M., Farhat, . K., Khan, . M. A., Ahmad, . B., Ali, . S. & Noor, . M. (2023) Clinical outcomes in type 2 diabetics switched to Insulin Degludec Aspart from conventional Premixed Insulin therapy. Rawal Medical Journal, 48 (4), 805-808.